Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions

A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions

The objective of this study is to evaluate the comparative bioavailability between Tamsulosin Hydrochloride 0.4 mg Capsules (Teva Pharmaceuticals USA) and Flomax® 0.4 mg Capsules (Boehringer Ingelheim Pharmaceuticals, Inc. USA), after a single-dose in healthy subjects under fasting conditions.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Tamsulosin; Drug: Tamsulosin

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M1R 5A3
      • Pharma Medica Research Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Healthy, non-smoking male subjects, 18 years of age or older.
• BMI greater than or equal to 19 and less than or equal to 30.

• Negative for:

  • HIV.
  • Hepatitis B surface antigen and Hepatitis C antibody.
  • Using drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).
  • Urine cotinine test
• No significant diseases or clinically significant findings in a physical examination.
• No clinically significant abnormal laboratory values.
• No clinically significant findings in vital signs measurements and a 12-lead electrocardiogram (ECG).
• Systolic blood pressure between 100-140 mmHg and diastolic blood pressure between 60-90 mmgHg.
• Be informed of the nature of the study and given written consent prior to receiving any study procedure.

Exclusion Criteria:

• Known history or presence of any clinically significant medical condition, illness or surgery within 4 weeks prior to drug administration.
• Known or suspected carcinoma.

• Known history or presence of:

  • Hypersensitivity or idiosyncratic reaction to tamsulosin and/or any other drug substances with similar activity.
  • Alcoholism within the last 12 months.
  • Drug dependence and/or substance abuse.
  • Use of tobacco or nicotine-containing products within the last 6 months.
• Use of any prescription medication within 14 days prior to Period 1 dosing. Use of any over the counter (OTC) medication within 7 days prior to Period 1 dosing.
• Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to Period 1 dosing.
• On a special diet within 4 weeks prior to drug administration (e.g. liquid, protein, raw food diet).
• Participated in another clinical trial or received and investigational product within 30 days prior to drug administration.
• Donated up to 250 mL of blood within the previous 30 days OR Donated from 251 to 500 mL of blood in the previous 45 days OR Donated more than 500 mL of blood in the previous 56 days (based on the Canadian Blood Services guideline for blood donation.
• Difficulty fasting or consuming the standard meals.
• Do not tolerate venipuncture.
• Unable to read or sign the ICF.

Study Plan

How is the study designed?

Design Details

• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Tamsulosin; 0.4 mg Capsule	Drug: Tamsulosin; Test 0.4 mg Capsule; Drug: Tamsulosin; Reference Listed 0.4 mg Capsule; Other Names: Flomax®
ACTIVE_COMPARATOR: Flomax®; 0.4 mg Capsule	Drug: Tamsulosin; Test 0.4 mg Capsule; Drug: Tamsulosin; Reference Listed 0.4 mg Capsule; Other Names: Flomax®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax (maximum observed concentration of drug substance in plasma)	Bioequivalence based on Cmax	Blood samples drawn over 60 hour time period
AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration)	Bioequivalence based on AUC0-t	Blood samples drawn over 60 hour time period
AUC0-inf (area under the concentration-time curve from time zero to infinity)	Bioequivalence based on AUC0-inf	Blood samples drawn over 60 hour time period

Collaborators and Investigators

• Sponsor: Teva Pharmaceuticals USA

Study record dates

Study Major Dates

• Study Start: December 1, 2004
• Primary Completion (ACTUAL): December 1, 2004
• Study Completion (ACTUAL): December 1, 2004

Study Registration Dates

• First Submitted: June 22, 2010
• First Submitted That Met QC Criteria: June 22, 2010
• First Posted (ESTIMATE): June 23, 2010

Study Record Updates

• Last Update Posted (ESTIMATE): June 23, 2010
• Last Update Submitted That Met QC Criteria: June 22, 2010
• Last Verified: June 1, 2010

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Urological Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Tamsulosin
• Other Study ID Numbers: 2004-824